Aug 2026· European Cardiology· Vol 21· 0 citations· 69 references
Medicine
TL;DR
Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in clinical trials.
Abstract
Aortic stenosis (AS) is the most common valvular heart disease in ageing populations and is associated with substantial morbidity and mortality. Despite advances in surgical and transcatheter valve replacement, no medical therapy has yet been shown to prevent disease onset or slow progression. Calcific AS is now recognised as an active, multifactorial process involving lipid infiltration, inflammation and osteogenic calcification of the aortic valve. Lipoprotein(a) has emerged as a key contributor to these mechanisms and is a genetically determined, lifelong cardiovascular risk factor. Lipoprotein(a) is a major carrier of oxidised phospholipids, which promote valvular inflammation and calcification. Epidemiological and Mendelian randomisation studies consistently demonstrate a strong and likely causal association between elevated lipoprotein(a) and AS. Experimental and translational data suggest that lipoprotein(a) exerts its effects early in the disease course, promoting valve inflammation and calcification before significant stenosis develops. The recent development of lipoprotein(a)-lowering therapies has renewed interest in targeting this pathway, raising the possibility that early lipoprotein(a)-lowering may modify disease progression, a hypothesis now being tested in clinical trials.
This narrative review summarizes the molecular biology, genetics, epidemiology, pathophysiological mechanisms, and clinical relevance of Lp(a), and critically examines current and emerging therapeutic strategies aimed at reducing Lp(a)-mediated cardiovascular risk.
L. Granata, Simona Giubilato, Francesca Campanella et al.· Frontiers in Medicine· 1 citation
PURPOSE OF REVIEW
Lipids and lipoproteins have established roles in calcific atherosclerosis, but there is less awareness of their role in calcific aortic valve disease (CAVD). Clinical studies link CAVD with severe hypercholesterolemia, and genetic studies consistently link it with lipoprotein little (a) [Lp(a)], a ma...
O. Aksoy, Y. Tintut, L. Demer· Current Opinion in Lipidolog...· 0 citations
Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...
P. Sabouret, Domenico Mario Giamundo, J. Popiołek-Kalisz et al.· Reviews in cardiovascular me...· 0 citations
Introduction. Elevated lipoprotein(a) has emerged as an important determinant of cardiovascular risk because of its roles in atherosclerotic disease, vascular inflammation, endothelial dysfunction, arterial stiffening, and vascular calcification. Increasing evidence suggests that the clinical significance of Lp(a) exte...
T. Solomenchuk, Rustam Zhurayev, V. Protsko et al.· Clinical and Preventive Medi...· 0 citations
Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality in developed countries. Although its clinical manifestations usually occur in adulthood, atherosclerotic damage may begin silently at an early age. Its main determinant is cumulative exposure to atherogenic lipoproteins.
Pediatric d...
Silvia Ibarra, L. Salamanca, Isabel González· Revista Pediatría Atención P...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.